搜索结果: 'methocult media formulations for human hematopoietic cells serum containing'

ImmunoCult™ 人Treg分化添加剂 人naïve CD4+ T细胞向调节性T细胞（Tregs）分化的无血清培养添加剂

IntestiCult™ 类器官生长基础培养基 (人) 用于建立和维持人结直肠癌类器官的培养基

IntestiCult™-SF 类器官生长培养基 (人) 用于构建和维持人肠类器官的无血清的非条件培养基

NeuroCult™ NS-A 基础培养基（人） 培养人神经干细胞和祖细胞的基础培养基

RosetteSep™人CD3去除抗体混合物 免疫密度去除试剂混合物

C. T. Charlesworth et al. (SEP 2018) Molecular therapy. Nucleic acids 12 89--104

Priming Human Repopulating Hematopoietic Stem and Progenitor Cells for Cas9/sgRNA Gene Targeting.

Engineered nuclease-mediated gene targeting through homologous recombination (HR) in hematopoietic stem and progenitor cells (HSPCs) has the potential to treat a variety of genetic hematologic and immunologic disorders. Here,we identify critical parameters to reproducibly achieve high frequencies of RNA-guided (single-guide RNA [sgRNA]; CRISPR)-Cas9 nuclease (Cas9/sgRNA) and rAAV6-mediated HR at the $\beta$-globin (HBB) locus in HSPCs. We identified that by transducing HSPCs with rAAV6 post-electroporation,there was a greater than 2-fold electroporation-aided transduction (EAT) of rAAV6 endocytosis with roughly 70{\%} of the cell population having undergone transduction within 2 hr. When HSPCs are cultured at low densities (1 × 105 cells/mL) prior to HBB targeting,HSPC expansion rates are significantly positively correlated with HR frequencies in vitro as well as in repopulating cells in immunodeficient NSG mice in vivo. We also show that culturing fluorescence-activated cell sorting (FACS)-enriched HBB-targeted HSPCs at low cell densities in the presence of the small molecules,UM171 and SR1,stimulates the expansion of gene-edited HSPCs as measured by higher engraftment levels in immunodeficient mice. This work serves not only as an optimized protocol for genome editing HSPCs at the HBB locus for the treatment of $\beta$-hemoglobinopathies but also as a foundation for editing HSPCs at other loci for both basic and translational research. View Publication

产品类型：

产品号#：

09605

09655

产品名：

StemSpan™ SFEM II

Lam AC et al. (DEC 2001) Transfusion 41 12 1567--76

Preclinical ex vivo expansion of cord blood hematopoietic stem and progenitor cells: duration of culture; the media, serum supplements, and growth factors used; and engraftment in NOD/SCID mice.

BACKGROUND: Ex vivo expansion of cord blood (CB) hematopoietic stem and progenitor cells increases cell dose and may reduce the severity and duration of neutropenia and thrombocytopenia after transplantation. This study's purpose was to establish a clinically applicable culture system by investigating the use of cytokines,serum-free media,and autologous plasma for the expansion of CB cells and the engraftment of expanded product in nonobese diabetic/severe combined immunodeficient (NOD/SCID) mice. STUDY DESIGN AND METHODS: Enriched CB CD34+ cells were cultured in four media (Iscove's modified Dulbecco's medium with FCS,Gibco; X-Vivo-10,BioWhittaker; QBSF-60,Quality Biological; and StemSpan SFEM,Stem Cell Technologies) with four cytokine combinations (thrombopoietin [TPO],SCF,Flt-3 ligand [FL] with and without G-CSF,and/or IL-6). The effect of autologous CB plasma was also investigated. The read-out measures were evaluated on Days 8 and 12. After expansion at the optimized condition,cultured cells were transplanted into sublethally irradiated NOD/SCID mice. The engraftment of human CD45+ cells and subsets in the bone marrow,spleen,and peripheral blood was determined. RESULTS: QBSF-60 or StemSpan SFEM supported high yields of early progenitors (CD34+ cells,textlessor= 64.8-fold; CD34+CD38- cells,330-fold; CFU-granulocyte erythroid macrophage megakaryocyte [GEMM],248-fold) and CFUs of the myeloid (CFU-GM,407-fold) and erythroid (BFU/CFU-E,144-fold) lineages. The expansion of the megakaryocytic lineage was consistently higher in X-Vivo-10 (CFU-megakaryocyte,684-fold). Autologous plasma promoted colony formation but reduced CD34+ cells and CFU-GEMM. The addition of G-CSF or IL-6 improved cell yields; G-CSF was more effective for committed progenitors. Expansion products from cultures in QBSF-60 with the cytokines engrafted and differentiated into the myeloid and lymphoid lineages in NOD/SCID mice. CONCLUSION: The data supported the strategy of expansion. The optimized condition may be applicable to clinical expansion for the abrogation or reduction of posttransplant cytopenia. View Publication

产品类型：

产品号#：

09600

09650

产品名：

StemSpan™ SFEM

J. W. Schott et al. (sep 2019) Molecular therapy. Methods {\&} clinical development 14 134--147

Enhancing Lentiviral and Alpharetroviral Transduction of Human Hematopoietic Stem Cells for Clinical Application.

Ex vivo retroviral gene transfer into CD34+ hematopoietic stem and progenitor cells (HSPCs) has demonstrated remarkable clinical success in gene therapy for monogenic hematopoietic disorders. However,little attention has been paid to enhancement of culture and transduction conditions to achieve reliable effects across patient and disease contexts and to maximize potential vector usage and reduce treatment cost. We systematically tested three HSPC culture media manufactured to cGMP and eight previously described transduction enhancers (TEs) to develop a state-of-the-art clinically applicable protocol. Six TEs enhanced lentiviral (LV) and five TEs facilitated alpharetroviral (ARV) CD34+ HSPC transduction when used alone. Combinatorial TE application tested with LV vectors yielded more potent effects,with up to a 5.6-fold increase in total expression of a reporter gene and up to a 3.8-fold increase in VCN. Application of one of the most promising combinations,the poloxamer LentiBOOST and protamine sulfate,for GMP-compliant manufacturing of a clinical-grade advanced therapy medicinal product (ATMP) increased total VCN by over 6-fold,with no major changes in global gene expression profiles or inadvertent loss of CD34+CD90+ HSPC populations. Application of these defined culture and transduction conditions is likely to significantly improve ex vivo gene therapy manufacturing protocols for HSPCs and downstream clinical efficacy. View Publication

产品类型：

产品号#：

19254

19254RF

产品名：

EasySep™人Naïve B细胞富集试剂盒

RoboSep™ 人Naïve B细胞富集试剂盒含滤芯吸头

科学海报

Optimized Media and Workflow for the Expansion of Human Pluripotent Stem Cells as Aggregates in Suspension Cultures

产品类型：

Conference：

ISSCR 2019

产品号#：

产品名：

技术手册

Human Colony-Forming Unit (CFU) Assays Using MethoCult™

产品类型：

产品号#：

00217

00217UK

00215

00215GER

00215UK

00602

00603

00606

00607

00608

00609

04436

04064

04100

04230

04236

04431

04434

04444

04464

04531

04535

04545

04536

04564

09300

04035

04330

04034

04044

04435

04445

04534

04544

04437

04447

00215US.4

00215CA.3

00215GER.3

0

产品名：

MethoCult™ SF H4436

MethoCult™ H4034 Optimum启动试剂盒套装

MethoCult™ H4100

MethoCult™H4230

MethoCult™SF H4236

MethoCult™H4431

MethoCult™H4434经典

MethoCult™ H4434 Classic启动试剂盒套装

MethoCult™H4531

MethoCult™H4535富集无EPO

MethoCult™ H4535 Enriched，不含EPO

MethoCult™ SF H4536

入门套件MethoCult™H4534经典无EPO

含有10% 牛血清白蛋白（BSA）的 Iscove's MDM

MethoCult™H4035 Optimum无EPO

MethoCult™H4330

MethoCult™H4034 Optimum

MethoCult™H4435富集

MethoCult™H4534经典无EPO

MethoCult™表达

造血祖细胞检测标准化培训课程

EasySep™人APC正选试剂盒II

对来源于外周血单个核细胞或其他单细胞悬液中标记 APC 缀合抗体的人细胞进行免疫磁珠正选分离

EasySep™人CD138正选试剂盒 II 人CD138+细胞的免疫磁珠正选

搜索结果: 'methocult media formulations for human hematopoietic cells serum containing'

Priming Human Repopulating Hematopoietic Stem and Progenitor Cells for Cas9/sgRNA Gene Targeting.

Preclinical ex vivo expansion of cord blood hematopoietic stem and progenitor cells: duration of culture; the media, serum supplements, and growth factors used; and engraftment in NOD/SCID mice.

Enhancing Lentiviral and Alpharetroviral Transduction of Human Hematopoietic Stem Cells for Clinical Application.

欢迎您关注STEMCELL Technologies的微信公众平台